Corvinus
Corvinus

High-sensitivity troponin T as a predictor of cardiovascular events in colorectal cancer patients undergoing chemotherapy: results of the COLOVASC prospective cohort study

Prohászka, Bence Imre ORCID: https://orcid.org/0000-0002-7068-0959, Sándor, Zsófia Andrea ORCID: https://orcid.org/0009-0005-2295-3106, Ferenci, Tamás ORCID: https://orcid.org/0000-0001-6791-3080, Gráf, László, Lohinszky, Júlia, Horváth, Anna ORCID: https://orcid.org/0000-0003-3229-5643, Tegze, Bálint ORCID: https://orcid.org/0000-0002-6127-6591, Tóth, Éva Katalin ORCID: https://orcid.org/0000-0001-9960-9833, Masszi, Tamás ORCID: https://orcid.org/0000-0003-2322-9863, Drobni, Zsófia ORCID: https://orcid.org/0000-0002-1355-5318, Cardinale, Daniela Maria and Pozsonyi, Zoltán ORCID: https://orcid.org/0000-0002-3098-2434 (2026) High-sensitivity troponin T as a predictor of cardiovascular events in colorectal cancer patients undergoing chemotherapy: results of the COLOVASC prospective cohort study. Frontiers in Cardiovascular Medicine, 13 . DOI https://doi.org/10.3389/fcvm.2026.1943142

[img]
Preview
PDF - Requires a PDF viewer such as GSview, Xpdf or Adobe Acrobat Reader
1MB

Official URL: https://doi.org/10.3389/fcvm.2026.1943142


Abstract

Background: Fluoropyrimidine-based chemotherapy is associated with cardiovascular events in patients with colorectal cancer, yet validated tools for pre-treatment cardiovascular risk stratification are lacking. Cardiac biomarkers are not routinely incorporated into baseline assessment and prospective evidence supporting their use remains limited. Objectives: Our aim was to determine whether baseline high-sensitivity troponin T (hs-TnT) provides prognostic information for major adverse cardiovascular events during chemotherapy in patients with colorectal cancer. Materials and methods: Within a prospective single-center observational cohort study at the Department of Internal Medicine and Hematology, Semmelweis University, consecutive patients with histologically confirmed newly diagnosed or recurrent colorectal cancer scheduled to receive 5-fluorouracil (5-FU)-based chemotherapy were enrolled between September 1, 2020, and June 2, 2024. Baseline hs-TnT concentrations were measured before treatment initiation, and patients were followed for the occurrence of major adverse cardiovascular events (MACEs). Independent predictors of MACE were identified using penalized multivariable logistic regression. Receiver operating characteristic (ROC) curve analysis evaluated the discriminatory performance of baseline hs-TnT and determined the optimal cut-off value using the Youden index. Adequacy index analysis assessed the relative prognostic contribution of hs-TnT to the multivariable model. Results: 180 patients were enrolled, with a median follow-up of 185 days, 44 patients (24.4%) experienced MACE, more than half of them occurred within the first two cycles of chemotherapy. Baseline hs-TnT demonstrated modest discrimination for predicting MACE (AUC 0.628, 95% CI 0.513–0.742). The optimal hs-TnT cut-off was 14 ng/L. In a multivariable analysis, elevated baseline hs-TnT (OR 2.35 per +10 ng/L, 95% CI 1.37–4.05) and Vascular Endothelial Growth Factor (VEGF)-inhibitor therapy (OR 2.38, 95% CI 1.23–4.60) were associated with MACEs. In a sensitivity analysis, excluding treatment-related hypertension from the composite endpoints, elevated baseline hs-TnT remained the only independent predictor. According to the adequacy index analysis, hs-TnT contributed 38.3% of the total prognostic information provided by the multivariable model. Conclusions: Baseline hs-TnT was independently associated with MACEs in patients with colorectal cancer receiving fluoropyrimidine-based chemotherapy. Although its discriminatory performance as a standalone biomarker was modest, hs-TnT provided incremental prognostic information for baseline cardiovascular risk assessment and may help identify patients who warrant closer cardiovascular surveillance.

Item Type:Article
Uncontrolled Keywords:colorectal cancer; risk stratification; troponin; CARDIOVASCULAR TOXICITY; Cardio-oncology; major cardiovascular events (MACEs); Chemotherapy
Divisions:Institute of Data Analytics and Information Systems
Subjects:Social welfare, insurance, health care
Funders:Hungarian Academy of Sciences
Projects:János Bolyai Research Scholarship
DOI:https://doi.org/10.3389/fcvm.2026.1943142
ID Code:13472
Deposited By: MTMT SWORD
Deposited On:10 Nov 2026 09:52
Last Modified:10 Nov 2026 09:52

Repository Staff Only: item control page

Downloads

Downloads per month over past year

View more statistics